When should a woman with polycystic ovary syndrome discontinue Ozempic (semaglutide) before attempting pregnancy?

When to Discontinue Ozempic Before Attempting Pregnancy in Women with PCOS

Women with PCOS must stop Ozempic (semaglutide) at least 2 months before attempting to conceive due to the drug's prolonged elimination half-life and potential teratogenic risks. 1

FDA-Mandated Discontinuation Timeline

• Discontinue Ozempic at least 2 months before planned pregnancy – this is the official FDA recommendation based on semaglutide's approximately 1-week elimination half-life and the need for complete drug washout before conception. 1

• The 2-month washout period accounts for semaglutide's long pharmacokinetic profile – with a half-life of approximately 1 week, multiple elimination cycles are required to clear the drug from maternal circulation and minimize fetal exposure risk. 1

Evidence for Teratogenic Risk

• Animal studies demonstrate fetal harm at clinically relevant exposures – in rats, rabbits, and cynomolgus monkeys, semaglutide caused visceral abnormalities (heart, blood vessels, kidney, liver), skeletal malformations (cranial bones, vertebrae, ribs, sternebra), early pregnancy losses, and reduced fetal growth at doses equivalent to or slightly above human therapeutic levels. 1

• Pharmacologically mediated maternal weight loss coincided with fetal abnormalities – the marked reductions in maternal body weight, weight gain, and food consumption observed across species were temporally associated with increased pregnancy losses and developmental defects. 1

Clinical Context: PCOS and Weight-Loss Medications

• Clinical practice guidelines recommend stopping all weight-loss medications before attempting conception – this applies broadly to women of childbearing age with obesity, including those with PCOS, to eliminate potential teratogenic exposures during the critical periconceptional and early embryonic periods. 2

• Metformin should be discontinued by the end of the first trimester when used for PCOS ovulation induction – unlike semaglutide, metformin may be continued through early pregnancy if used to treat polycystic ovary syndrome, but should be stopped after the first trimester unless another indication (e.g., type 2 diabetes) exists. 2

Practical Algorithm for Discontinuation

Step 1: Confirm the patient is actively planning pregnancy (not just considering it in the distant future).

Step 2: Stop Ozempic immediately and document the discontinuation date. 1

Step 3: Wait a minimum of 2 months (8 weeks) before attempting conception. 1

Step 4: During the washout period, transition to non-pharmacologic PCOS management:

• Implement structured lifestyle modification targeting ≥5% weight loss through a 500–750 kcal daily deficit. 3, 4
• Continue metformin 1500–2550 mg daily if already prescribed for metabolic optimization and insulin resistance. 3, 4
• Ensure effective contraception during the 2-month washout to prevent unintended pregnancy exposure. 1

Step 5: After the 2-month washout, initiate ovulation induction with clomiphene citrate 50–150 mg daily for 5 days as first-line fertility treatment. 3, 5

Common Pitfalls to Avoid

• Do not continue Ozempic "just a little longer" to achieve additional weight loss – the 2-month washout is non-negotiable, and any delay in discontinuation postpones the ability to safely conceive. 1

• Do not assume metformin and semaglutide have the same pregnancy safety profile – metformin has a more favorable safety profile in pregnancy and may be continued through the first trimester for PCOS, whereas semaglutide must be stopped 2 months before conception. 2, 1

• Do not rely on barrier contraception alone during the washout period – given the high fertility potential in PCOS patients who have achieved weight loss with semaglutide, use highly effective contraception (e.g., combined oral contraceptives, intrauterine device) during the 2-month washout to prevent inadvertent drug exposure in early pregnancy. 1

• Do not restart semaglutide postpartum without counseling on breastfeeding – semaglutide is present in rat milk at levels 3–12 fold lower than maternal plasma, and the effects on human milk and breastfed infants are unknown. 1

Evidence on Semaglutide Benefits in PCOS (Context for Discontinuation Decision)

• Semaglutide combined with metformin produces superior weight loss and metabolic improvements compared to metformin alone – in a 16-week randomized trial, combination therapy resulted in 6.09 kg weight loss versus 2.25 kg with metformin monotherapy, along with greater reductions in testosterone, visceral adiposity, and C-reactive protein. 6

• Real-world semaglutide use in obese women with PCOS achieved 11.4% total body weight loss – in a retrospective study of 58 women treated for a median of 12 months, 81% lost >5% of total body weight, with significant improvements in blood pressure, HbA1c, and cholesterol. 7

• Despite these metabolic benefits, the teratogenic risk mandates discontinuation before conception – the FDA's 2-month washout requirement reflects the balance between semaglutide's therapeutic advantages in PCOS and the documented fetal harm in animal studies. 1